Soy Isoflavones and Bone Health: Focus on theRANKL/RANK/OPG Pathway

Publish Year: 1402
نوع سند: مقاله کنفرانسی
زبان: English
View: 38

This Paper With 12 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

ICFBCNF07_110

تاریخ نمایه سازی: 16 اسفند 1402

Abstract:

Bone remodels via resorption and formation, two phenomena that continuously occur in bone turnover. The RANKL/RANK/ OPG pathway is one of the several mechanisms that affect bone turnover. The RANKL/OPG ratio has a substantial role in bone resorption. An imbalance between formation and resorption is related to an increased RANKL/OPG balance. OPG, a member of this system, can bind to RANKL and suppress RANK-RANKL interaction, and subsequently, inhibit further osteoclastogenesis. The serum levels of RANKL and OPG in the bone microenvironment are vital for osteoclasts formation. The RANK/RANKL/OPG system plays a role in the pathogenesis of bone disorders. This system can be considered a new treatment target for bone disorders. Soy isoflavones affect the RANK/RANKL/OPG system through numerous mechanisms. Soy isoflavones decrease RANKL levels and increase OPG levels. Therefore, isoflavones improve bone metabolism and decrease bone resorption. Soy isoflavones decrease serum markers of bone resorption and improve bone metabolism. However, while the available data are promising, the results of several studies reported no change in RANKL and OPG levels with isoflavones supplementation. In this regard, current evidence is insufficient for conclusive approval of the efficacy of isoflavones on RANKL/RANK/OPG and further research, including animal and human studies, are needed to confirm the effect of soy isoflavones on the RANKL/RANK/OPG pathway. This study was a review of available evidence to determine the role of isoflavones in bone hemostasis and the RANK/RANKL/OPG pathway. The identification of the effects of isoflavones on the RANKL/RANK/OPG pathway directs future studies and leads to the development of effective treatment strategies for bone disorders.

Authors

Saeedeh Hosseini Hooshiar

Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of MedicalSciences, Kashan, IR, Iran

Mohammad Tobeiha

Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of MedicalSciences, Kashan, IR, Iran

Sadegh Jafarnejad

Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of MedicalSciences, Kashan, IR, Iran